Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
July 22, 2024 09:05 ET
|
Autonomix Medical, Inc.
Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device...
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement
July 18, 2024 08:30 ET
|
Autonomix Medical, Inc.
Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared ablation technology from RF Innovations, Inc. THE WOODLANDS, TX, July 18, 2024 (GLOBE...
Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
July 15, 2024 08:00 ET
|
Autonomix Medical, Inc.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA...
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform
July 11, 2024 09:00 ET
|
Autonomix Medical, Inc.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Access the Autonomix CEO Corner Here! THE WOODLANDS, TX, July 11,...
Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment
July 03, 2024 09:00 ET
|
Autonomix Medical, Inc.
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company’s ongoing human clinical trial THE...
Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
June 18, 2024 08:00 ET
|
Autonomix Medical, Inc.
The first five patients successfully completed protocols with no immediate procedural-related complications or significant adverse events; Pain relief for responder group was experienced as quick as 1...
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
June 17, 2024 16:05 ET
|
Autonomix Medical, Inc.
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024
June 10, 2024 08:00 ET
|
Autonomix Medical, Inc.
Management to host live webcast to discuss results on Tuesday, June 18th at 8:30 a.m. ET THE WOODLANDS, TX, June 10, 2024 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
June 03, 2024 08:15 ET
|
Autonomix Medical, Inc.
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
May 31, 2024 08:05 ET
|
Autonomix Medical, Inc.
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate...